PT  - JOURNAL ARTICLE
AU  - Ladage, Dennis
AU  - Rösgen, Delia
AU  - Schreiner, Clemens
AU  - Ladage, Dorothee
AU  - Adler, Christoph
AU  - Harzer, Oliver
AU  - Braun, Ralf J.
TI  - Persisting antibody response to SARS-CoV-2 in a local Austrian population
AID  - 10.1101/2020.11.20.20232140
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.11.20.20232140
4099  - http://medrxiv.org/content/early/2020/11/23/2020.11.20.20232140.short
4100  - http://medrxiv.org/content/early/2020/11/23/2020.11.20.20232140.full
AB  - The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic. The prevalence and persistence of antibodies following a peak SARS-CoV-2 infection provides insights into the potential for some level of population immunity. In June 2020 we succeeded in testing almost half of the population of an Austrian township with a higher incidence for COVID-19 infections. Now we performed a follow-up study to reassess the prevalence of SARS-CoV-2-specific IgA and IgG antibodies. In 121 people, including 68 participants of the previous study we found the prevalence of IgG and IgA antibodies remaining remarkably stable with 84% of our cohort prevailing SARS-CoV-2-specific antibodies, which is only a slight decrease from 93% four months before. Most patients with confirmed COVID-19 seroconvert, potentially providing immunity to reinfection. Our results suggest a stable antibody response that we observed for at least six months post infection with implications for developing strategies for testing and protecting the population.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialStudy is not registered as it does not fulfill the definition of a clinical trialFunding StatementNo external funding to reportAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was a priori due to its design exempted from local ethics committee ruling (decision by head of the ethics committee of Lower Austria).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo supplementary to this manuscript, all original data is available on request